{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T03:08:49Z","timestamp":1784689729656,"version":"3.55.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DK069350"],"award-info":[{"award-number":["DK069350"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DK095944"],"award-info":[{"award-number":["DK095944"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Food and Drug Administration","award":["002525"],"award-info":[{"award-number":["002525"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.beem.2014.09.001","type":"journal-article","created":{"date-parts":[[2014,9,10]],"date-time":"2014-09-10T07:19:34Z","timestamp":1410333574000},"page":"47-55","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Parathyroid hormone therapy for hypoparathyroidism"],"prefix":"10.1016","volume":"29","author":[{"given":"Natalie E.","family":"Cusano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mishaela R.","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Bilezikian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beem.2014.09.001_bib1","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1002\/jbmr.483","article-title":"Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research","volume":"26","author":"Bilezikian","year":"2011","journal-title":"J\u00a0Bone Mineral Res"},{"key":"10.1016\/j.beem.2014.09.001_bib2","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/s12020-012-9618-y","article-title":"Mini-review: new therapeutic options in hypoparathyroidism","volume":"41","author":"Cusano","year":"2012","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2014.09.001_bib3","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1056\/NEJMcp0803050","article-title":"Clinical practice. Hypoparathyroidism","volume":"359","author":"Shoback","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2014.09.001_bib4","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.1210\/jc.2012-1808","article-title":"Long-term follow-up of patients with hypoparathyroidism","volume":"97","author":"Mitchell","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metabolism"},{"key":"10.1016\/j.beem.2014.09.001_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1472-6823-13-1","article-title":"Increased vertebral morphometric fracture in patients with postsurgical hypoparathyroidism despite normal bone mineral density","volume":"13","author":"Mendonca","year":"2013","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.beem.2014.09.001_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/jbmr.2273","article-title":"Post-surgical hypoparathyroidism \u2013 risk of fractures, psychiatric diseases, cancer, cataract, and infections","author":"Underbjerg","year":"2014","journal-title":"J\u00a0Bone Mineral Res"},{"key":"10.1016\/j.beem.2014.09.001_bib7","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1002\/jbmr.2004","article-title":"Prevalence and incidence of hypoparathyroidism in the United States using a large claims database","volume":"28","author":"Powers","year":"2013","journal-title":"J\u00a0Bone Mineral Res"},{"key":"10.1016\/j.beem.2014.09.001_bib8","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1056\/NEJM199610103351505","article-title":"A\u00a0familial syndrome of hypocalcemia with hypercalciuria due to mutations in the calcium-sensing receptor","volume":"335","author":"Pearce","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2014.09.001_bib9","first-page":"3792","article-title":"A\u00a0novel mutation of the signal peptide of the preproparathyroid hormone gene associated with autosomal recessive familial isolated hypoparathyroidism","volume":"84","author":"Sunthornthepvarakul","year":"1999","journal-title":"J\u00a0Clin Endocrinol Metabolism"},{"key":"10.1016\/j.beem.2014.09.001_bib10","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1172\/JCI100224","article-title":"Studies on the physiology of the parathyroid glands: I. calcium and phosphorus studies on a case of idiopathic hypoparathyroidism","volume":"7","author":"Albright","year":"1929","journal-title":"J\u00a0Clin Investestigation"},{"key":"10.1016\/j.beem.2014.09.001_bib11","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1007\/s00198-009-1149-x","article-title":"Therapy of hypoparathyroidism with intact parathyroid hormone","volume":"21","author":"Rubin","year":"2010","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2014.09.001_bib12","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1210\/jc.2012-2984","article-title":"Therapy of hypoparathyroidism with PTH(1-84): a prospective four-year investigation of efficacy and safety","volume":"98","author":"Cusano","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metabolism"},{"key":"10.1016\/j.beem.2014.09.001_bib13","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1002\/jbmr.470","article-title":"The effect of adding PTH(1-84) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study","volume":"26","author":"Sikjaer","year":"2011","journal-title":"J\u00a0Bone Mineral Res"},{"key":"10.1016\/j.beem.2014.09.001_bib14","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(13)70106-2","article-title":"Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study","volume":"1","author":"Mannstadt","year":"2013","journal-title":"Lancet Diabetes & Endocrinol"},{"key":"10.1016\/j.beem.2014.09.001_bib15","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1210\/jc.2002-021736","article-title":"Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium","volume":"88","author":"Winer","year":"2003","journal-title":"J\u00a0Clin Endocrinol Metabolism"},{"key":"10.1016\/j.beem.2014.09.001_bib16","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1210\/jc.2009-2464","article-title":"Long-term treatment of 12 children with chronic hypoparathyroidism: a randomized trial comparing synthetic human parathyroid hormone 1-34 versus calcitriol and calcium","volume":"95","author":"Winer","year":"2010","journal-title":"J\u00a0Clin Endocrinol Metabolism"},{"key":"10.1016\/j.beem.2014.09.001_bib17","first-page":"391","article-title":"Synthetic human parathyroid hormone 1-34 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism","volume":"97","author":"Winer","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metabolism"},{"key":"10.1016\/j.beem.2014.09.001_bib18","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1002\/jbmr.1627","article-title":"Daily parathyroid hormone 1-34 replacement therapy for hypoparathyroidism induces marked changes in bone turnover and structure","volume":"27","author":"Gafni","year":"2012","journal-title":"J\u00a0Bone Mineral Res"},{"key":"10.1016\/j.beem.2014.09.001_bib19","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1530\/eje.0.1460215","article-title":"Well-being, mood and calcium homeostasis in patients with hypoparathyroidism receiving standard treatment with calcium and vitamin D","volume":"146","author":"Arlt","year":"2002","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2014.09.001_bib20","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1210\/jc.2013-1239","article-title":"The effect of PTH(1-84) on quality of life in hypoparathyroidism","volume":"98","author":"Cusano","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metabolism"},{"key":"10.1016\/j.beem.2014.09.001_bib21","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1007\/s00198-014-2677-6","article-title":"Effects of PTH(1-84) therapy on muscle function and quality of life in hypoparathyroidism: results from a randomized controlled trial","volume":"25","author":"Sikjaer","year":"2014","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2014.09.001_bib22","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2014-2267","article-title":"PTH(1-84) is associated with improved quality of life in hypoparathyroidism through 5 Years of Therapy","author":"Cusano","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metabolism"},{"key":"10.1016\/j.beem.2014.09.001_bib23","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1002\/jbmr.452","article-title":"PTH(1-84) administration reverses abnormal bone-remodeling dynamics and structure in hypoparathyroidism","volume":"26","author":"Rubin","year":"2011","journal-title":"J\u00a0Bone Mineral Res"},{"key":"10.1016\/j.beem.2014.09.001_bib24","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1359\/jbmr.080803","article-title":"Dynamic and structural properties of the skeleton in hypoparathyroidism","volume":"23","author":"Rubin","year":"2008","journal-title":"J\u00a0Bone Mineral Res"},{"key":"10.1016\/j.beem.2014.09.001_bib25","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/jbmr.1493","article-title":"Changes in 3-dimensional bone structure indices in hypoparathyroid patients treated with PTH(1-84): a randomized controlled study","volume":"27","author":"Sikjaer","year":"2012","journal-title":"J\u00a0Bone Mineral Res"},{"key":"10.1016\/j.beem.2014.09.001_bib26","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.bone.2008.09.019","article-title":"Cancellous and cortical bone architecture and turnover at the iliac crest of postmenopausal osteoporotic women treated with parathyroid hormone 1-84","volume":"44","author":"Recker","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.beem.2014.09.001_bib27","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s00223-011-9500-6","article-title":"Teriparatide in bisphosphonate-resistant osteoporosis: microarchitectural changes and clinical results after 6 and 18 months","volume":"89","author":"Jobke","year":"2011","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.beem.2014.09.001_bib28","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1359\/jbmr.2001.16.10.1846","article-title":"Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study","volume":"16","author":"Dempster","year":"2001","journal-title":"J\u00a0Bone Mineral Res"},{"key":"10.1016\/j.beem.2014.09.001_bib29","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1080\/01926230252929882","article-title":"Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety","volume":"30","author":"Vahle","year":"2002","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.beem.2014.09.001_bib30","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1080\/01926230601072301","article-title":"Defining a noncarcinogenic dose of recombinant human parathyroid hormone 1-84 in a 2-year study in Fischer 344 rats","volume":"34","author":"Jolette","year":"2006","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.beem.2014.09.001_bib31","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1002\/jbmr.1768","article-title":"The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years","volume":"27","author":"Andrews","year":"2012","journal-title":"J\u00a0Bone Mineral Res"},{"key":"10.1016\/j.beem.2014.09.001_bib32","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1002\/jbmr.1800","article-title":"Safety of osteoanabolic therapy: a decade of experience","volume":"27","author":"Cipriani","year":"2012","journal-title":"J\u00a0Bone Mineral Res"},{"key":"10.1016\/j.beem.2014.09.001_bib33","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s11095-010-0192-9","article-title":"Parathyroid hormone (1-34)-coated microneedle patch system: clinical pharmacokinetics and pharmacodynamics for treatment of osteoporosis","volume":"28","author":"Daddona","year":"2011","journal-title":"Pharm Res"},{"key":"10.1016\/j.beem.2014.09.001_bib34","series-title":"The endocrine Society's 94th annual meeting and Expo. Houston, TX OR08\u20131","article-title":"Bone anabolic efficacy and safety of BA058, a novel analog of hPTHrP: results from a phase 2 clinical trial in postmenopausal women with osteoporosis","author":"Hattersley","year":"2012"},{"key":"10.1016\/j.beem.2014.09.001_bib35","first-page":"3480","article-title":"A\u00a0randomized, cross-over trial of once-daily versus twice-daily parathyroid hormone 1-34 in treatment of hypoparathyroidism","volume":"83","author":"Winer","year":"1998","journal-title":"J\u00a0Clin Endocrinol Metabolism"},{"key":"10.1016\/j.beem.2014.09.001_bib36","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1210\/jc.2007-2552","article-title":"Effects of once versus twice-daily parathyroid hormone 1-34 therapy in children with hypoparathyroidism","volume":"93","author":"Winer","year":"2008","journal-title":"J\u00a0Clin Endocrinol Metabolism"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X1400102X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X1400102X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:48:46Z","timestamp":1761497326000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X1400102X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S1521690X1400102X"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2014.09.001","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Parathyroid hormone therapy for hypoparathyroidism","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2014.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}